Aapro M et al. Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol 2008;19(3):420-32. Abstract

Brufsky AM. Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors. Curr Oncol Rep 2008;10(1):18-26. Abstract

Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast 2007a;16(3):223-34. Abstract

Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: A new frontier in symptom management for breast cancer survivors. J Clin Oncol 2007b;25(25):3797-9. No abstract available

Cella D et al. Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100(3):273-84. Abstract

Coleman RE et al. Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations. Cancer Treat Rev 2008;34(3):275-82. Abstract

Crew KD et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007;25(25):3877-83. Abstract

Derzko C et al. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol 2007;14(Suppl 1):20-40. Abstract

Eastell R et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26(7):1051-7. Abstract

Glaus A et al. Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 2006;17(5):801-6. Abstract

Gnant M et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008;9(9):840-9. Abstract

Hadji P. Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr Relat Cancer 2008;15(1):73-90. Abstract

Hershman DL. Getting a grip on aromatase inhibitor-associated arthralgias. J Clin Oncol 2008;26(19):3120-1. Abstract

Marx RE et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567-75. Abstract

Morales L et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 2008;26(19):3147-52. Abstract

Presant CA et al. Aromatase inhibitor associated arthralgia and/or bone pain: Frequency and characterization in nonclinical trial patients. Clin Breast Cancer 2007;7(10):775-8. Abstract

Reid DM et al. Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treat Rev 2008;34(Suppl 1):3-18. Abstract

Ruggiero SL et al. Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Prac 2006;2(1):7-14. Available at: http://jop.stateaffiliates-asco.org/JanuaryIssue/7.pdf.